INTRA-CELLULAR THERAPIES INC. overview

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Intra-Cellular Therapies, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors PR Newswire NEW YORK, Aug. 4, 2022 NEW YORK , Aug. 4, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Intra-Cellular Therapies, Inc. (NASDAQ: ITCI). If you are a shareholder...

LOS ANGELES, CA / ACCESSWIRE / June 18, 2022 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors ofIntra-Cellular Therapies, Inc. ("Intra-Cellular" or "the Company") (NASDAQ: ITCI ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. If you are a shareholder who suffered a...

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intra-Cellular Therapies, Inc. (“Intra-Cellular” or “the Company”) (NASDAQ: ITCI ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. If you are a shareholder who suffered a loss, click here to participate . We...

Key Binding Characteristics of Dusquetide to Important Intracellular Protein Identified PR Newswire PRINCETON, N.J., June 1, 2022 Paper published in the Journal Structure PRINCETON, N.J. , June 1, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today a publication describing the binding of its Innate...

Thinking about buying stock in Intra-Cellular Therapies, Selecta Biosciences, Coherus Biosciences, ImmunityBio, or SeaChange International? PR Newswire NEW YORK, Dec. 20, 2021 NEW YORK , Dec. 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ITCI, SELB, CHRS, IBRX, and SEAC. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. ITCI:...

SUWON, Republic of Korea, May 24, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc . (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced that the Company has received a notice of allowance from the United States Patent and Trademark Office for an enhanced platform technology that aims to improve the potency of RNAi therapeutics by increasing delivery of siRNA to target cells. The technology will be applied initially to the Company’s investigational therapeutics targeting...

Complix Signs Global Drug Discovery and Development Agreement with I-Mab to Develop Cell Penetrating Alphabodies against Two Intracellular Immuno-oncology Targets PR Newswire HASSELT, Belgium, March 10, 2021 - Complix retains joint development and commercialization rights outside Greater China - Complix to receive upfront fees and research funding as well as potential milestone and royalty payments HASSELT, Belgium , March 10, 2021 /PRNewswire/ -- Complix, a biopharmaceutical company developing...